Kronos Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KRON research report →
Range $1 – $2.25
Price Chart
About the company
Kronos Bio, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the identification and advancement of innovative therapies for cancer. Its therapeutic strategy centers on modulating dysregulated transcription factors and the intricate transcriptional regulatory networks that fuel oncogenic activity.
- CEO
- Deborah A. Knobelman
- IPO
- 2020
- Employees
- 8
- HQ
- San Mateo, CA, US
Get TickerSpark's AI analysis on KRON
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $53.65M
- P/E
- -0.62
- PEG
- -0.01
- P/S
- 5.45
- P/B
- 0.60
- EV/EBITDA
- 0.10
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -943.21%
- Net Margin
- -874.08%
- ROE
- -69.80%
- ROIC
- -80.16%
Latest fiscal year · YoY change
- Revenue
- $9.85M+56.6%
- Gross Profit
- $9.85M+56.6%
- Op Income
- $-92,887,000
- Net Income
- $-86,079,000+23.6%
- EPS
- $-1.43+26.7%
- OCF Growth
- +16.7%
- FCF Growth
- +17.4%
- 52W High
- $1.46
- 52W Low
- $0.65
- 50D MA
- $0.80
- 200D MA
- $0.90
- Beta
- 1.64
- RSI (14)
- 66
- Avg Volume
- 855.96K
No earnings-call transcripts are available for KRON yet.
- Free Float
- 96.6%
- Shares Outstanding
- 60.97M
- Float Shares
- 58.90M
of shares held by institutions
48 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 874.10K | ▼ 35.35K |
| Pathstone Family Office, LLC | 12.03K | 0 |
Held by 1 ETFs
Biggest fund positions in KRON by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 20, 25 | Belldegrun Arie | sell | 34,000 |
| Jun 20, 25 | Belldegrun Arie | sell | 20,600 |
| Jun 20, 25 | Belldegrun Arie | other | 679,575 |
| Jun 20, 25 | Belldegrun Arie | sell | 34,000 |
| Jun 20, 25 | Belldegrun Arie | sell | 34,000 |
| Jun 20, 25 | BISCHOFBERGER NORBERT W | other | 263,750 |
| Jun 20, 25 | BISCHOFBERGER NORBERT W | sell | 297,186 |
| Jun 20, 25 | BISCHOFBERGER NORBERT W | sell | 400,000 |
| Jun 20, 25 | BISCHOFBERGER NORBERT W | sell | 570,868 |
| Jun 20, 25 | BISCHOFBERGER NORBERT W | sell | 699,800 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KRON coverage
Recent articles, reports, and earnings notes.
No research on KRON yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KRON report →Kronos Bio Completes Sale to Concentra Biosciences
marketwatch.com · Jun 20
KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON
businesswire.com · May 4
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc. - KRON
prnewswire.com · May 1
Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders
businesswire.com · May 1
KRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to Shareholders
businesswire.com · May 1
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
globenewswire.com · May 1
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
globenewswire.com · Mar 18
Kronos Bio Announces CEO Transition and Reduction in Force
globenewswire.com · Nov 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.